Analyst Ratings for Monopar Therapeutics (MNPR)
MNPR Rating Summary
MNPR Price Target Summary
- Highest: $145.00 (Barclays)
- Lowest: $100.00 (Chardan)
- Average: $122.30
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$122.30 (+76.6%)
* Over Last 12-Mos
Rating Score: 8.8 / 10
Percentile Rank: 88%
Avg. $ Target:
$122.30 (+76.6%)
* Over Last 12-Mos
Rating Score: 8.8 / 10
Percentile Rank: 88%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/13/2026 | Cantor Fitzgerald | Kirsten Kluska | Downgrade | Neutral (Overweight) |
119.00 (109.00) |
114.46 (69.27) |
-39.48% | Details |
| 4/6/2026 | Jones Trading | Boris Peaker | New Coverage | Buy (N/A) |
130.00 (N/A) |
55.13 (69.27) |
25.65% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
